Evidence map›Paper›PMID 31263279›Full record

ArticleNature immunology2019

c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies.

Jochem H Bernink, Yoichiro Ohne, Marcel B M Teunissen, Jingya Wang, Jincheng Wu, Lisette Krabbendam, Christine Guntermann, Richard Volckmann, Jan Koster, Sophie van Tol and 6 more

Erratum issuedOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Nature immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 126 papers.

0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

126 citing papers in PubMed, 187 citations in OpenAlex.

  1. Article
  2. Article
  3. Shared Pathways between Psoriasis and Atopic Dermatitis.Dermatology practical & conceptual · 2026
    Review
  4. Article
  5. Review
  6. ILC2s and their immune checkpoints in the antitumor response.Journal for immunotherapy of cancer · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

66 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 3 countries.

Jochem H BerninkDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Yoichiro OhneDepartment of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA.
Marcel B M TeunissenDepartment of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0003-1119-6662
Jingya WangDepartment of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA.
Jincheng WuDepartment of Research Bioinformatics, MedImmune LLC, Gaithersburg, MD, USA.
Lisette KrabbendamDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Christine GuntermannAutoimmunity, Transplantation, and Inflammation Disease Area, Novartis Institutes for BioMedical Research, Basel, Switzerland.ORCID http://orcid.org/0000-0001-8220-2578
Richard VolckmannDepartment of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.
Jan KosterDepartment of Oncogenomics, Academic Medical Center, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-0890-7585
Sophie van TolDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Ivan RamirezDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-6302-0020
Yashaswi ShresthaDepartment of Translational Medicine and Pharmacogenomics, MedImmune LLC, Gaithersburg, MD, USA.ORCID http://orcid.org/0000-0002-5567-0277
Menno A de RieDepartment of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Hergen SpitsDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. hergen.spits@amc.uva.nl.ORCID http://orcid.org/0000-0003-3269-8338
Xavier Romero RosDepartment of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
Alison A HumblesDepartment of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA. alisonhumbles@gmail.com.ORCID http://orcid.org/0000-0003-0045-9340
Amsterdam UMC Location University of Amsterdam · NLInstitute of Neuroimmunology of the Slovak Academy of Sciences · SKNovartis (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we identify a group 2 innate lymphoid cell (ILC2) subpopulation that can convert into interleukin-17 (IL-17)-producing NKp44

Indexed as

Cells, CulturedHumansInterleukin-17Interleukin-1betaInterleukin-23 Subunit p19Interleukin-4LymphocytesNuclear Receptor Subfamily 1, Group F, Member 3Proto-Oncogene Proteins c-kitPsoriasisReceptors, CCR10SkinTransforming Growth Factor betaCCR10 protein, humanIL17A protein, humanIL1B protein, humanIL23A protein, humanIL4 protein, humanInterleukin-17Interleukin-1betaInterleukin-23 Subunit p19Interleukin-4KIT protein, humanNuclear Receptor Subfamily 1, Group F, Member 3Proto-Oncogene Proteins c-kitReceptors, CCR10RORC protein, humanTransforming Growth Factor beta

Identifiers

PMID31263279
OpenAlexW2955613592

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.